The role of cancer-associated myofibroblasts in intrahepatic cholangiocarcinoma

Nature Reviews Gastroenterology and Hepatology

Volumn 9, Issue 1, 2012, Pages 44-54

  Sirica, Alphonse E ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CD163 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; DOXORUBICIN; GELATINASE A; GELATINASE B; GEMCITABINE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN SNAI1; SCATTER FACTOR; SOMATOMEDIN BINDING PROTEIN 5; SORAFENIB; STROMAL CELL DERIVED FACTOR 1; THROMBOSPONDIN 1; TRANSCRIPTION FACTOR RUNX2; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKER; UNCLASSIFIED DRUG; VASCULOTROPIN; WNT1 PROTEIN; ZINC FINGER PROTEIN;

APOPTOSIS; BILE DUCT CARCINOMA; CANCER CELL; CANCER CELL DESTRUCTION; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CELL FUNCTION; COCULTURE; DISEASE ASSOCIATION; DRUG TARGETING; EXTRACELLULAR MATRIX; HUMAN; METASTASIS; MOLECULARLY TARGETED THERAPY; MYOFIBROBLAST; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; REVIEW; TUMOR VASCULARIZATION;

ANIMALS; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; FIBROBLASTS; HUMANS; SIGNAL TRANSDUCTION;

EID: 84655169986     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2011.222     Document Type: Review

References (160)

1. Patel, T. Cholangiocarcinoma\-controversies and challenges. Nat Rev. Gastroenterol. Hepatol. 8, 189-200 (2011).
2. Ellis, M. C. et al. Surgical treatment of intrahepatic cholangiocarcinoma: outcomes and predictive factors. HPB (Oxford) 13, 59-63 (2011).
3. Shin, H.-R. et al. Epidemiology of cholangiocarcinoma: an update focusing on risk factors. Cancer Sci. 101, 579-585 (2010).
4. Cardinale, V et al. Intra-hepatic and extra-hepatic cholangiocarcinoma: new insight into epidemiology and risk factors. World J. Gastrointest. Oncol. 2, 407-416 (2010).
5. Nakanuma, Y. et al. Pathological classification of intrahepatic cholangiocarcinoma based on a new concept. World J. Hepatol. 2, 419-427 (2010).
6. Sirica, A. E. et al. Intrahepatic cholangiocarcinoma progression: prognostic factors and basic mechanisms. Clin. Gastroenterol. Hepatol. 7 (Suppl.), S68-S78 (2009).
7. Gatto, M. & Alvaro, D. Cholangiocarcinoma: risk factors and clinical presentation. Eur. Rev. Med. Pharmacol. Sci. 14, 363-367 (2010).
8. Gatto, M. et al. Cholangiocarcinoma: update and future perspectives. Dig. Liver Dis. 42, 253-260 (2010).
9. Sempoux, C. et al. Intrahepatic cholangiocarcinoma: new insights in pathology. Semin. Liver Dis. 31, 49-60 (2011).
10. Zografos, G. N., Farfaras, A., Zagouri, F., Chrysikos, D. & Karaliotas, K. Cholangiocarcinoma: principles and current trends. Hepatobiliary Pancreat Dis. Int. 10, 10-20 (2011).
11. Shirakawa, H. et al. Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer. Int. J. Oncol. 34, 649-656 (2009).
12. Kajiyama, K., Maeda, T., Takenaka, K., Sugimachi, K. & Tsuneyoshi, M. The significance of stromal desmoplasia in intrahepatic cholangiocarcinoma: a special reference of 'scirrhous-type' and 'nonscirrhous-type' growth. Am. J. Surg. Pathol. 23, 892-902 (1999). (Pubitemid 29360106)
13. Sirica, A. E., Campbell, D. J. & Dumur, C. I. Cancer-associated fibroblasts in intrahepatic cholangiocarcinoma. Curr. Opin. Gastroenterol. 27, 276-284 (2011).
14. Hartel, M. et al. Desmoplastic reaction influences pancreatic cancer growth behavior World J. Surg. 28, 818-825 (2004). (Pubitemid 39315401)
15. Angeli, F., Koumakis, G., Chen, M.-C., Kumar, S. & Delinassios, J. G. Role of stromal fibroblasts in cancer: promoting or impeding- Tumour Biol. 30, 109-120 (2009).
16. Chuaysri, C. et al. α-Smooth muscle actin- positive fibroblasts promote biliary cel proliferation and correlate with poor survival in cholangiocarcinoma. Oncol. Rep. 21, 957-969 (2009).
17. Okabe, H. et al. Hepatic stellate cells may relate to progression of intrahepatic cholangiocarcinoma. Ann. Surg. Oncol. 16, 2555-2564 (2009).
18. Dranoff, J. A. & Wells, R. G. Portal fibroblasts: underappreciated mediators of biliary fibrosis. Hepatology 51, 1438-1444 (2010).
19. Quante, M. et al. Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell 19, 257-272 (2011).
20. Ishii, G. et al. Bone-marrow-derived myofibroblasts contribute to the cancer-induced stromal reaction. Biochem. Biophys. Res. Commun. 309, 232-240 (2003).
21. Li, T. et al. Epithelial-mesenchymal transition nduced by hepatitis C virus core protein in cholangiocarcinoma. Ann. Surg. Oncol. 17, 1937-1944 (2010).
22. Korita, P. V. et al. Aberrant expression of vimentin correlates with dedifferentiation and poor prognosis in patients with intrahepatic cholangiocarcinoma. Anticancer Res. 30, 2279-2285 (2010).
23. Sato, Y. et al. Epithelial-mesencymal transition nduced by transforming growth factor- β 1/Snai activation aggravates invasive growth of cholangiocarcinoma. Am. J. Pathol. 177, 141-152 (2010).
24. Aishima, S. et al. Lymphatic spread is related to VEGF-C expression and D2-40-positive myofibroblasts in intrahepatic cholangiocarcinoma. Mod. Pathol. 21, 256-264 (2008). (Pubitemid 351304278)
25. + fibroblasts are more nvolved in the progression of hilar/ extrahepatic cholangiocarcinoma than of peripheral intrahepatic cholangiocarcinoma. Histopathology 55, 423-431 (2009).
26. Hasita, H. et al. Significance of alternatively activated macrophages in patients with ntrahepatic cholangiocarcinoma. Cancer Sci. 101, 1913-1919 (2010).
27. 4ntegrin and the PI3K pathway. Oncogene 26, 2082-2094 (2007). (Pubitemid 46514745)
28. Kanno, A. et al. Periostin, secreted from stromal cells, has biphasic effect on cel migration and correlates with the epithelial to mesenchymal transition of human pancreatic cancer cells. Int. J. Cancer 122, 2707-2718 (2008). (Pubitemid 351631372)
29. Utispan, K. et al. Gene expression profiling of cholangiocarcinoma- derived fibroblast reveals alterations related to tumor progression and ndicates periostin as a poor prognostic marker. Molecular Cancer 9, 13 (2010).
30. Michaylira, C. Z. et al. Periostin, a cell adhesion molecule, facilitates invasion in the tumor microenvironment and annotates a novel tumor-invasive signature in esophageal cancer. Cancer Res. 70, 5281-5292 (2010).
31. Aishima, S. et al. Tenascin expression at the nvasive front is associated with poor prognosis n intrahepatic cholangiocarcinoma. Mod. Pathol. 16, 1019-1027 (2003). (Pubitemid 37280818)
32. Chen, J. et al. Role of fibrillar tenascin-C in metastatic pancreatic cancer. Int. J. Oncol. 34, 1029-1036 (2009).
33. Date, K. et al. Inhibition of tumor growth and nvasion by a four-kringle antagonist (HGF/NK4) for hepatocyte growth factor. Oncogene 17, 3045-3054 (1998). (Pubitemid 29012208)
34. Matsumoto, K. & Nakamura, T. Hepatocyte growth factor and the Met system as a mediator of tumor-stromal interactions. Int. J. Cancer 119, 477-483 (2006). (Pubitemid 43955698)
35. Menakongka, A. & Suthiphongchai, T. Involvement of PI3K and ERK1/2 pathways in hepatocyte growth factor-induced cholangiocarcinoma cell invasion. World J. Gastroenterol. 16, 713-722 (2010).
36. Grugan, K. D. et al. Fibroblast-secreted hepatocyte growth factor plays a functional role n esophageal squamous cell carcinoma nvasion. Proc. Natl Acad. Sci. USA 107, 11026-11031 (2010).
37. Ohira, S. et al. Possible regulation of migration of intrahepatic cholangiocarcinoma cells by nteraction of CXCR4 expressed in carcinoma cells with tumor necrosis factor-α and stromal- derived factor-1 released in stroma. Am. J. Pathol. 168, 1155-1168 (2006).
38. Leelawat, K., Leelawat, S., Narong, S. & Hongeng, S. Roles of the MEK1/2 and AKT pathways in CXCL12/CXCR4 induced cholangiocarcinoma cell invasion. World J. Gastroenterol. 13, 1561-1568 (2007). (Pubitemid 46672665)
39. Tanaka, S. et al. Human WISP1v, a member of the CCN family, is associated with invasive cholangiocarcinoma. Hepatology 37, 1122-1129 (2003). (Pubitemid 36538689)
40. Bao, S. et al. Periostin potently promotes metastatic growth of colon cancer by augmenting cell survival via the Akt/PKB pathway. Cancer Cell 5, 329-339 (2004). (Pubitemid 38482069)
41. Ruan, K., Bao, S. & Ouyang, G. The multifaceted role of periostin in tumorigenesis. Cell. Mol. Life Sci. 66, 2219-2230 (2009).
42. Fingas, C. D. et al. Myofibroblast-derived PDGF-BB promotes Hedgehog signaling- dependent resistance to TRAIL cytotoxicity in cholangiocarcinoma cells [abstract]. Gastroenterol. 140 (Suppl.), S909 (2011).
43. Vandoros, G. P. et al. PPAR-γ is expressed and NF- κB pathway is activated and correlates positively with COX-2 expression in stromal myofibroblasts surrounding colon adenocarcinomas. J. Cancer Res. Clin. Oncol. 132, 76-84 (2006). (Pubitemid 41752048)
44. Omura, N. et al. Cyclooxygenase-deficient pancreatic cancer cells use exogenous sources of prostaglandins. Mol. Cancer Res. 8, 821-832 (2010).
45. Davaille, J., Li, L., Mallat, A. & Lotersztajn, S. Sphingosine 1-phosphate triggers both apoptotic and survival signals for human hepatic myofibroblasts. J. Biol. Chem. 277, 37323-37330 (2002).
46. Dumur, C. I., Campbell, D. J. W., DeWitt, J. L., Oyesanya, R. A. & Sirica, A. E. Differential gene expression profiling of cultured neu- transformed versus spontaneously- transformed rat cholangiocytes and of corresponding cholangiocarcinomas. Exp. Mol. Pathol. 89, 227-235 (2010).
47. Ponnusamy, S. et al. Sphingolipids and cancer: ceramide and sphingosine-1-phosphate in the regulation of cell death and drug resistance. Future Oncol. 6, 1603-1624 (2010).
48. Kawahara, N. et al. Enhanced expression of thrombospondin-1 and hypovascularity in human cholangiocarcinoma. Hepatology 28, 1512-1517 (1998). (Pubitemid 28549120)
49. Tang, D. et al. Angiogenesis in cholangiocellular carcinoma: expression of vascular endothelial growth factor, angiopoietin-1/2, thrombospondin-1 and clinicopathological significance. Oncol. Rep. 15, 525-532 (2006).
50. Shimizu, K. Pancreatic stellate cells: molecular mechanism of pancreatic fibrosis. J. Gastroenterol. Hepatol. 23 (Suppl. 1), S119-S121 (2008). (Pubitemid 351389042)
51. Li, Z. et al. Transforming growth factor- β and substrate stiffness regulate portal fibroblast activation in culture. Hepatology 46, 1246-1256 (2007). (Pubitemid 350144789)
52. Kinnman, N. et al. The myofibroblastic conversion of peribiliary fibrogenic cells distinct from hepatic stellate cells is stimulated by platelet-derived growth factor during liver fibrogenesis. Lab. Invest. 83, 163-173 (2003). (Pubitemid 36255362)
53. Li, G. et al. RNA interfering connective tissue growth factor prevents rat hepatic stellate cel activation and extracellular matrix production. J. Gene Med. 10, 1039-1047 (2008).
54. Hong, F. et al. Hepatic stellate cells express functional CXCR4: role in stromal cell-derived factor-1α-mediated stellate cell activation. Hepatology 49, 2055-2067 (2009).
55. Maeda, N. et al. Stimulation of proliferation of rat hepatic stellate cells by galectin-1 and galectin-3 through different intracellular signaling pathways. J. Biol. Chem. 278, 18938-18944 (2003). (Pubitemid 36799277)
56. Fitzner, B. et al. Galectin-1 is an inductor of pancreatic stellate cell activation. Cell Signal. 17, 1240-1247 (2005). (Pubitemid 40982614)
57. Okamoto, K. et al. Angiotensin II induces tumor progression and fibrosis in intrahepatic cholangiocarcinoma through an interaction with hepatic stellate cells. Int. J. Oncol. 37, 1251-1259 (2010).
58. Nishino, R. et al. Identification of novel candidate tumour marker genes for intrahepatic cholangiocarcinoma. J. Hepatol. 49, 207-216 (2008).
59. Yasuoka, H. et al. The fibrotic phenotype induced by IGFBP-5 is regulated by MAPK activation and Egr-1-dependent and -independent mechanisms. Am. J. Pathol. 175, 605-615 (2009).
60. Sureshbabu, A. et al. IGFBP-5 induces epithelial and fibroblast responses consistent with the fibrotic response. Biochem. Soc. Trans. 37, 882-885 (2009).
61. Liu, L.-X. et al. Insulin-like growth factor binding protein-7 induces activation and transdifferentiation of hepatic stellate cells in vitro. World J. Gastroenterol. 15, 3246-3253 (2009).
62. Terada, T., Okada, Y. & Nakanuma, Y. Expression of immunoreactive matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in human normal livers and primary liver tumors. Hepatology 23, 1341-1344 (1996). (Pubitemid 26181214)
63. Cohen, S. J. et al. Fibroblast activation protein and its relationship to clinical outcome in pancreatic adenocarcinoma. Pancreas 37, 154-158 (2008).
64. Räsänen, K. & Vaheri, A. Activation of fibroblasts in cancer stroma. Exp. Cell Res. 316, 2713-2722 (2010).
65. Prakobwong, S. et al. Involvement of MMP-9 in peribiliary fibrosis and cholangiocarcinogenesis via Rac1-dependent DNA damage in a hamster model. Int. J. Cancer 127, 2576-2587 (2010).
66. Bornstein, P. Matricellular proteins: an overview. J. Cell Commun. Signal. 3, 163-165 (2009).
67. Kii, I. et al. Incorporation of tenascin-C into the extracellular matrix by periostin underlies an extracellular meshwork architecture. J. Biol. Chem. 285, 2028-2039 (2010).
68. Symoens, S. et al. Identification of binding partners interacting with the α1-N.-propeptide of type V collagen. Biochem. J. 433, 371-381 (2011).
69. To, W. S. & Midwood, K. S. Identification of novel and distinct binding sites within tenascin-C for soluble and fibrillar fibronectin. J. Biol. Chem. 286, 14881-14891 (2011).
70. Chiquet-Ehrismann, R. & Tucker, R. P. Tenascins and the importance of adhesion modulation. Cold Spring Harb. Perspect Biol. 3, http://dx.doi. org/10.1101/cshperspect.a004960 (2011).
71. Okamura, N. et al. Cellular and stromal characteristics in the scirrhous hepatocellular carcinoma: comparison with hepatocellular carcinomas and intrahepatic cholangiocarcinomas. Pathol. Int. 55, 724-731 (2005). (Pubitemid 41726939)
72. 5 integrins and promotes cell motility. Cancer Res. 62, 5358-5364 (2002). (Pubitemid 35024613)
73. Orend, G. & Chiquet-Ehrismann, R. Tenascin-C induced signaling in cancer. Cancer Lett. 244, 143-163 (2006) (Pubitemid 44508708)
74. Jang, J.-H. & Chung, C.-P. Tenascin-C promotes cell survival by activation of Akt in human chondrosarcoma cell. Cancer Lett. 229, 101-105 (2005). (Pubitemid 41262545)
75. Nagaharu, K. et al. Tenascin C induces epithelial-mesenchymal transition-like change accompanied by SRC activation and focal adhesion kinase phosphorylation in human breast cancer cells. Am. J. Pathol. 178, 754-763 (2011).
76. Liu, Y & Liu, B.-A. Enhanced proliferation, invasion, and epithelial-mesenchymal transition of nicotine-promoted gastric cancer by periostin. World J. Gastroenterol. 17, 2674-2680 (2011).
77. Tucker, R. P. & Chiquet-Ehrismann, R. The regulation of tenascin expression by tissue microenvironments. Biochim. Biophys. Acta 1793, 888-892 (2009).
78. Pongchairerk, U., Guan, J. L & Leardkamolkarn, V. Focal adhesion kinase and Src phosphorylations in HGF-induced proliferation and invasion of human cholangiocarcinoma cell line, HuCCA-1. World J. Gastroenterol. 11, 5845-5852 (2005). (Pubitemid 41662837)
79. De Wever, O. et al. Tenascin-C and SF/HGF produced by myofibroblasts in vitro provide convergent proinvasive signals to human colon cancer cells through RhoA and Rac. FASEB J. 18, 1016-1018 (2004). (Pubitemid 39561510)
80. Taraseviciute, A., Vincent, B. T., Schedin, P. & Jones, P. L. Quantitative analysis of three- dimensional human mammary epithelial tissue architecture reveals a role for Tenascin-C in regulating c-Met function. Am. J. Pathol. 176, 827-838 (2010).
81. Ohira, S. et al. Local balance of transforming growth factor-ß1 secreted from cholangiocarcinoma cells and stromal-derived factor-1 secreted from stromal fibroblasts is a factor involved in invasion of cholangiocarcinoma. Pathol. Int. 56, 381-389 (2006). (Pubitemid 43886802)
82. Maroni, P., Bendinelli, P., Matteucci, E. & Desiderio, M. A. HGF induces CXCR4 and CXCL12-mediated tumor invasion through Ets1 and NFκ-B. Carcinogenesis 28, 267-279 (2007). (Pubitemid 46321842)
83. Tu, H. et al. CXCR4 and SDF-1 production are stimulated by hepatocyte growth factor and promote glioma cell invasion. Onkologie 32, 331-336 (2009).
84. Esencay, M., Newcomb, E. W. & Zagzag, D. HGF upregulates CXCR4 expression in gliomas via NFκ-B: implications for glioma cell migration. J. Neurooncol. 99, 33-40 (2010).
85. Majka, M. et al. SDF-1 alone and in co-operation with HGF regulates biology of human cervical carcinoma cells. Folia Histochem. Cytobiol. 44, 155-164 (2006). (Pubitemid 44131982)
86. Fujita, H. et al. Tumor-stromal interactions with direct cell contacts enhance proliferation of human pancreatic carcinoma cells. Cancer Sci. 100, 2309-2317 (2009).
87. Jiang, L. et al. Global hypomethylation of genomic DNA in Cancer-associated myofibroblasts. Cancer Res. 68, 9900-9908 (2008).
88. Shimoda, M., Mellody, K. T. & Orimo, A. Cancer- associated fibroblasts are a rate-limiting determinant for tumour progression. Semin. Cell Dev. Biol. 21, 19-25 (2010).
89. Schrader, J. et al. Matrix stiffness modulates proliferation, chemotherapeutic response, and dormancy in hepatocellular carcinoma cells. Hepatology 53, 1192-1205 (2011).
90. Miyamoto, H. et al. Tumor-stroma interaction of human pancreatic cancer: acquired resistance to anticancer drugs and proliferation regulation is dependent on extracellular matrix proteins. Pancreas 28, 38-44 (2004). (Pubitemid 38032243)
91. Ide, T. et al. The hypoxic environment in tumor- stromal cells accelerates pancreatic cancer progression via the activation of paracrine hepatocyte growth factor/c-Met signaling. Ann. Surg. Oncol. 14, 2600-2607 (2007). (Pubitemid 47389573)
92. Giaccia, A. J. & Schipani, E. Role of carcinoma- associated fibroblasts and hypoxia in tumor progression. Curr. Top. Microbiol. Immunol. 345, 31-45 (2010).
93. Omenetti, A. & Diehl, A. M. Hedgehog signaling in cholangiocytes. Curr. Opin. Gastroenterol. 27, 268-275 (2011).
94. Walter, K. et al. Overexpression of smoothened activates the sonic hedgehog signaling pathway in pancreatic Cancer-associated fibroblasts. Clin. Cancer Res. 16, 1781-1789 (2010).
95. Finger, E. C. & Giaccia, A. J. Hypoxia, inflammation, and the tumor microenvironment in metastatic disease. Cancer Metastasis Rev. 29, 285-293 (2010).
96. Kitajima, Y., Ide, T., Ohtsuka, T & Miyazaki, K. Induction of hepatocyte growth factor activator gene expression under hypoxia activates the hepatocyte growth factor/c-Met system via hypoxia inducible factor-1 in pancreatic cancer. Cancer Sci. 99, 1341-1347 (2008). (Pubitemid 351761722)
97. Erkan, M. et al. Cancer-stellate cell interactions perpetuate the hypoxia-fibrosis cycle in pancreatic ductal adenocarcinoma. Neoplasia 11, 497-508 (2009).
98. Ouyang, G. et al. Upregulated expression of periostin by hypoxia in non-small-cell lung cancer cells promotes cell survival via the Akt/PKB pathway. Cancer Lett. 281, 213-219 (2009).
99. Chu, S.-H. et al. Stabilization of hepatocyte growth factor mRNA by hypoxia-inducible factor 1. Mol. Biol. Rep. 36, 1967-1975 (2009).
100. Liu, H. et al. Hypoxic preconditioning advances CXCR4 and CXCR7 expression by activating HIF-1α in MSCs. Biochem. Biophys. Res. Commun. 401, 509-515 (2010).
101. Zhao, X.-Y. et al. Hypoxia inducible factor-1 mediates expression of galectin-1: the potential role in migration/invasion of colorectal cancer cells. Carcinogenesis 31, 1367-1375 (2010).
102. Distler, J. H. W. et al. Hypoxia-induced increase in the production of extracellular matrix proteins in systemic sclerosis. Arthritis Rheum. 56, 4203-4215 (2007). (Pubitemid 350262349)
103. Schwalm, S. et al. Sphingosine kinase-1 is a hypoxia-regulated gene that stimulates migration of human endothelial cells. Biochem. Biophys. Res. Commun. 368, 1020-1025 (2008).
104. Park, S. Y et al. Expression of MUC1, MUC2, MUC5AC and MUC6 in cholangiocarcinoma: prognostic impact. Oncol. Rep. 22, 649-657 (2009).
105. Aubert, S. et al. MUC1, a new hypoxia inducible factor target gene, in an actor in clear renal cel carcinoma tumor progression. Cancer Res. 69, 5707-5715 (2009).
106. Berman, D. M. et al. Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature 425, 846-851 (2003). (Pubitemid 37351469)
107. Inaguma, S., Kasai, K. & Ikeda, H. GLI1 facilitates the migration and invasion of pancreatic cancer cells through MUC5AC- mediated attenuation of E-cadherin. Oncogene 30, 714-723 (2011).
108. Yang, L. et al. Sonic hedgehog is an autocrine viability factor for myofibroblastic hepatic stellate cells. J. Hepatol. 48, 98-106 (2008). (Pubitemid 350191986)
109. Theunissen, J.-W. & de Sauvage, F. J. Paracrine hedgehog signaling in cancer. Cancer Res. 69, 6007-6010 (2009).
110. Choi, S. S. et al. Hedgehog pathway activation and epithelial-to- mesenchymal transitions during myofibroblastic transformation of rat hepatic cells in culture and cirrhosis. Am. J. Physiol. Gastrointest Liver Physiol. 297, G1093-G1106 (2009).
111. Sun, S. et al. Hypoxia-inducible factor-1α induces Twist expression in tubular epithelial cells subjected to hypoxia, leading to epithelial-to-mesenchymal transition. Kidney Int 75, 1278-1287 (2009).
112. Bechtel, W. & Zeisberg, M. Twist: a new link from hypoxia to fibrosis. Kidney Int. 75, 1255-1256 (2009).
113. Onishi, H. et al. Hypoxia activates the hedgehog signaling pathway in a ligand-independent manner by upregulation of Smo transcription in pancreatic cancer. Cancer Sci. 102, 1144-1150 (2011).
114. Jhandier, M. N., Kruglov, E. A., Lavoie, E. G., Sévigny, J. & Dranoff, J. A. Portal fibroblasts regulate the proliferation of bile duct epithelia via expression of NTPDase2. J. Biol. Chem. 280, 22986-22992 (2005). (Pubitemid 40853208)
115. Okabe, H. et al. Hepatic stellate cells accelerate the malignant behavior of cholangiocarcinoma cells. Ann. Surg. Oncol. 18, 1175-1184 (2011).
116. Sirica, A. E., Campbell, D. J. & Dumur, C. I. Cancer-associated fibroblastic cells significantly promote cholangiocarcinoma cell ductal growth in a novel 3-D co-culture model [abstract]. Gastroenterology 140 (Suppl. 1), S909-S910 (2011).
117. Lai, G.-H. et al. erbB-2/neu transformed rat cholangiocytes recapitulate key cellular and molecular features of human bile duct cancer. Gastroenterology 129, 2047-2057 (2005). (Pubitemid 41772979)
118. Sirica, A. E. et al. A novel "patient-like" model of cholangiocarcinoma progression based on bile duct inoculation of tumorigenic rat cholangiocyte cell lines. Hepatology 47, 1178-1190 (2008). (Pubitemid 351547904)
119. Blechacz, B. R. A. et al. Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2. Hepatology 50, 1861-1870 (2009).
120. Zhang, Z. et al. Preclinical assessment of simultaneous targeting of epidermal growth factor receptor (ERBB1) and ERBB2 as a strategy for cholangiocarcinoma therapy Hepatology 52, 975-986 (2010).
121. Ramanathan, R. K. et al. A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemother. Pharmacol. 64, 777-783 (2009).
122. Nakamura, I. & Roberts, L. R. Myc, Max, and Mnt: molecular mechanisms of enhancement of cholangiocarcinogenesis by cholestasis. Gastroenterology 141, 32-34 (2011).
123. Wiedmann, M. W. & Mössner, J. Molecular targeted therapy of biliary tract cancer\-results of the first clinical studies. Curr. Drug Targets 11, 834-850 (2010).
124. Zhu, A. X. & Hezel, A. F. Development of molecularly targeted therapies in biliary tract cancers: reassessing the challenges and opportunities. Hepatology 53, 695-704 (2011).
125. Chometon, G. & Jendrossek, V. Targeting the tumour stroma to increase efficacy of chemo- and radiotherapy. Clin. Transl. Oncol. 11, 75-81 (2009).
126. Maeda, T. et al. Clinicopathological correlates of aspartyl (asparaginyl) β -hydroxylase over- expression in cholangiocarcinoma. Cancer Detect. Prev. 28, 313-318 (2004). (Pubitemid 39471274)
127. Naran, S., Zhang, X. & Hughes, S. J. Inhibition of HGF/MET as therapy for malignancy. Expert Opin. Ther. Targets 13, 569-581 (2009).
128. Underiner, T. L., Herbertz, T. & Miknyoczki, S. J. Discovery of small molecule c-Met inhibitors: evolution and profiles of clinical candidates. Anticancer Agents Med. Chem. 10, 7-27 (2010).
129. Zhang, Y.-W. et al. MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor- dependent fashion to suppress carcinoma growth. Cancer Res. 70, 6880-6890 (2010).
130. Liang, X. CXCR4, inhibitors and mechanisms of action. Chem. Biol. Drug Des. 72, 97-110 (2008).
131. Singh, B. et al. Evaluation of a CXCR4 antagonist in a xenograft mouse model of inflammatory breast cancer. Clin. Exp. Metastasis 27, 233-240 (2010).
132. Jinawath, A., Akiyama, Y., Sripa, B. & Yuasa, Y Dual blockade of the Hedgehog and ERK1/2 pathways coordinately decreases proliferation and survival of cholangiocarcinoma cells. J. Cancer Res. Clin. Oncol. 133, 271-278 (2007).
133. Olive, K. P. et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324, 1457-1461 (2009).
134. Feldmann, G. et al. An orally bioavailable small- molecule inhibitor of Hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer. Mol. Cancer Ther. 7, 2725-2735 (2008).
135. Low, J. A. & de Sauvage, F. J. Clinical experience with Hedgehog pathway inhibitors. J. Clin. Oncol. 28, 5321-5326 (2010).
136. Holcombe, R. F., Gu, M., Imagawa, D. & Milovanovic, T. Expression of Kit and platelet- derived growth factor receptors α and β in cholangiocarcinoma, and case report of therapy with imatinib mesylate (STI571). Anticancer Drugs 14, 651-657 (2003). (Pubitemid 37297265)
137. Aoki, M. et al. Imatinib mesylate inhibits cel invasion of malignant peripheral nerve sheath tumor induced by platelet-derived growth factor-BB. Lab. Invest. 87, 767-779 (2007). (Pubitemid 47077256)
138. Shen, J. et al. Development of a fully human anti-PDGFRβ antibody that suppresses growth of human tumor xenofrafts and enhances antitumor activity of an anti-VEGFR2 antibody. Neoplasia 11, 594-604 (2009).
139. Edman, K. et al. The discovery of MMP7 inhibitors exploiting a novel selectivity trigger. Chem. Med. Chem. 6, 769-773 (2011).
140. Dings, R. P. M. et al. Inhibiting tumor growth by targeting tumor vasculature with galectin-1 antagonist anginex conjugated to the cytotoxic acylfulvene, 6-hydroxylpropylacylfulvene. Bioconjugate Chem. 21, 20-27 (2010).
141. Wu, M.-H. et al. Targeting galectin-1 in carcinoma- associated fibroblasts inhibits oral squamous cell carcinoma metastasis by downregulating MCP-1/CCL2 expression. Clin. Cancer Res. 17, 1306-1316 (2011).
142. Reardon, D. A., Zalutsky, M. R. & Bigner, D. D. AntiTenascin-C monoclonal antibody radioimmunotherapy for malignant glioma patients. Expert Rev. Anticancer Ther. 7, 675-687 (2007). (Pubitemid 46805563)
143. Tai, I. T., Dai, M. & Chen, L. B. Periostin induction in tumor cell line explants and inhibition of in vitro cell growth by anti-periostin antibodies. Carcinogenesis 26, 908-915 (2005). (Pubitemid 41214319)
144. Rathinam, R. & Alahari, S. K. Important role of integrins in the cancer biology. Cancer Metastasis Rev. 29, 223-237 (2010).
145. Desgrosellier, J. S. & Cheresh, D. A. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev. Cancer 10, 9-22 (2010).
146. Kufe, D. W. Functional targeting of the MUC1 oncogene in human cancers. Cancer Biol. Ther. 8, 1197-1203 (2009).
147. Zhou, Y, Rajabi, H. & Kufe, D. Mucin 1 C-terminal subunit oncoprotein is a target for small molecule inhibitors. Mol. Pharmacol. 79, 886-893 (2011).
148. Shida, D., Takabe, K., Kapitonov, D., Milstien, S. & Spiegel, S. Targeting SphK1 as a new strategy against cancer. Curr. Drug Targets 9, 662-673 (2008).
149. Maeda, T. et al. Antisense oligodeoxynucleotides directed against aspartyl (asparaginyl) β -hydroxylase suppress migration of carcinoma cells. J. Hepatol. 38, 615-622 (2003). (Pubitemid 36560646)
150. Edosada, C. Y et al. Selective inhibition of fibroblast activation protein protease based on dipeptide substrate specificity. J. Biol. Chem. 281, 7437-7444 (2006). (Pubitemid 43847515)
151. Santos, A. M., Jung, J., Aziz, N., Kissil, J. L. & Puré, E. Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice. J. Clin. Invest. 119, 3613-3625 (2009).
152. Loeffler, M., Krüger, J. A., Niethammer, A. G. & Reisfeld, R. A. Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J. Clin. Invest. 116, 1955-1962 (2006). (Pubitemid 44033319)
153. Wen, Y et al. Immunotherapy targeting fibroblast activation protein inhibits tumor growth and increases survival in a murine colon cancer model. Cancer Sci. 101, 2325-2332 (2010).
154. Schwartz, D. L. et al. The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects. Mol. Cancer Ther. 8, 947-958 (2009).
155. Semenza, G. L. Defining the role of hypoxia- inducible factor 1 in cancer biology and therapeutics. Oncogene 29, 625-634 (2010).
156. Lin, L. et al. The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF- β signaling. Oncogene 28, 961-972 (2009).
157. Lin, L. et al. Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells. Cancer Res. 70, 2445-2454 (2010).
158. Leelawat, K., Sakchinabut, S., Narong, S. & Wannaprasert, J. Detection of serum MMP-7 and MMP-9 in cholangiocarcinoma patients: evaluation of diagnostic accuracy. BMC Gastroenterol. 9, 30 (2009).
159. Leelawat, K., Narong, S., Wannaprasert, J. & Ratanashuek, T. Prospective study of MMP7 serum levels in the diagnosis of cholangiocarcinoma. World J. Gastroenterol. 16, 4697-4703 (2010).
160. Fujimoto, K. et al. Periostin, a matrix protein, has potential as a novel serodiagnostic marker for cholangiocarcinoma. Oncol. Rep. 25, 1211-1216 (2011).